{
    "Rank": 719,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03480152",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "180074"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "18-C-0074"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "National Institutes of Health Clinical Center (CC)",
                    "OrgClass": "NIH"
                },
                "BriefTitle": "Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer",
                "OfficialTitle": "A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2020",
                "OverallStatus": "Terminated",
                "WhyStopped": "slow accrual",
                "StartDateStruct": {
                    "StartDate": "May 18, 2018",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 25, 2019",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "November 5, 2019",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "March 27, 2018",
                "StudyFirstSubmitQCDate": "March 28, 2018",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "March 29, 2018",
                    "StudyFirstPostDateType": "Actual"
                },
                "ResultsFirstSubmitDate": "April 7, 2020",
                "ResultsFirstSubmitQCDate": "April 7, 2020",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "April 24, 2020",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "May 22, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 2, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Steven Rosenberg, M.D.",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "National Cancer Institute (NCI)"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "National Cancer Institute (NCI)",
                    "LeadSponsorClass": "NIH"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "Yes",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Background:\n\nExome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. In this study, researchers will make a treatment called a messenger ribonucleic acid (mRNA) vaccine. The vaccine might cause certain tumors to shrink.\n\nObjective:\n\nTo see if the mRNA vaccine is safe and can cause metastatic melanoma or epithelial tumors to shrink.\n\nEligibility:\n\nPeople 18-70 years old with metastatic melanoma or epithelial cancer\n\nDesign:\n\nParticipants will be screened under protocol 99-C-0128.\n\nParticipants will provide samples under protocol 03-C-0277:\n\nParticipants will provide a piece of their tumor from a previous surgery or biopsy.\n\nParticipants will have leukapheresis: Blood is removed through a needle in one arm and circulated through a machine that takes out the white blood cells. The blood is then returned through a needle in the other arm.\n\nParticipants will have many tests:\n\nScans and x-rays\n\nHeart and lung function tests\n\nBlood and urine tests\n\nParticipants will receive the mRNA vaccine every 2 weeks for up to 8 weeks. They will get the vaccine as an injection into the upper arm or thigh. They may receive a second course of vaccines if the study doctor determines it is needed.\n\nParticipants will have follow-up visits approximately 2 weeks after their final vaccine, then 1 month later, then every 1-2 months for the first year, and then once a year for up to 5 years. Each visit may take up to 2 days and include:\n\nPhysical exam\n\nBlood tests\n\nScans\n\nLeukapheresis at the first visit",
                "DetailedDescription": "Background:\n\nTherapeutic vaccination against cancer has proven very challenging with little clinical benefit.\nVaccines against non-viral tumors have mainly targeted differentiation antigens, cancer testis antigens, and overexpressed antigens. However, negative selection in the thymus against these normal non-mutated antigens severely limits the ability to generate high avidity anti-cancer T-cells. Such depletion can impair their antitumor activity and limit tumor elimination.\nThe National Cancer Institute Surgery Branch (NCI-SB) has developed a pipeline for the identification of immunogenic T-cell epitopes derived from neoantigens.\nIn recent studies, we identified the neoantigens recognized by tumor-infiltrating lymphocytes (TIL) that mediated regression in patients with metastatic melanoma. Using whole exome sequencing of a resected metastatic nodule followed by high throughput immunologic screening, we were able to demonstrate that tumor regressions were associated with the recognition by the administered TIL of unique somatic mutations that occurred in the cancer.\nWe also found that TIL from 29 of 32 patients with a wide variety of metastatic gastrointestinal cancers contained lymphocytes that recognized unique mutations presented in that patient's cancer.\nWe, therefore, aim to use this pipeline to identify immunogenic neoantigens and to predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and to use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine.\n\nObjectives\n\nPrimary objectives:\n\nDetermine the clinical response rate in patients with metastatic melanoma, gastrointestinal or genitourinary cancers who receive NCI-4650\nDetermine the safety of NCI-4650 in patients with metastatic melanoma, gastrointestinal or genitourinary cancers\n\nEligibility\n\nAge greater than or equal to 18 years and less than or equal to 70 years\nEvaluable metastatic melanoma, gastrointestinal, or genitourinary cancers refractory to standard of care treatment\nMetastatic cancer lesions suitable for surgical resection to perform whole exome sequencing and preparation of TIL\n\nDesign:\n\nPatients with metastatic cancer will undergo surgical resection of tumor followed by exome and RNA sequencing to identify expressed mutations. This will be conducted under the NCI-SB cell harvest protocol 03-C-0277. (Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).\nImmunogenic neoantigens will be identified from TIL by high throughput immunologic screening using long peptides and tandem minigenes covering all mutated epitopes.\nUp to 15 predicted neoantigens will be selected based on exome and RNA sequencing and their binding affinity to the patient HLA molecules.\nThe mRNA vaccine will be manufactured and supplied as Current Good Manufacturing Practice (cGMP) product by ModernaTX, Inc.\nThe patient will be vaccinated with mRNA containing epitopes from immunogenic neoantigens, predicted neoantigens and mutations in tumor suppressor or driver genes.\nThe mRNA vaccine will be administered intramuscularly (IM) for four cycles every two weeks. A patient may receive a second course for a total of eight cycles given.\nBlood samples will be taken every two weeks (during the vaccination period) and at each follow-up visit, and patients will be monitored for the quantity and quality of circulating neoantigen-specific T-cells."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Melanoma",
                        "Colon Cancer",
                        "Gastrointestinal Cancer",
                        "Genitourinary Cancer",
                        "Hepatocellular Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Metastatic Cancer",
                        "Immunotherapy",
                        "Tumor Regression",
                        "Cancer Vaccine",
                        "Gene Therapy"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1",
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Non-Randomized",
                    "DesignInterventionModel": "Sequential Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "5",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "1/Phase - Escalating doses of mRNA vaccine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Escalating doses of messenger ribonucleic acid (mRNA) vaccine",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "2/Phase II -MTD of mRNA vaccine established in Phase I",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine",
                            "InterventionDescription": "Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "1/Phase - Escalating doses of mRNA vaccine",
                                    "2/Phase II -MTD of mRNA vaccine established in Phase I"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Number of Participants Who Had a Clinical Response (Complete Response + Partial Response) to Treatment (Objective Tumor Regression)",
                            "PrimaryOutcomeDescription": "Clinical response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.",
                            "PrimaryOutcomeTimeFrame": "up to 12 months"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Number of Non-Serious Adverse Events Probably Related to Treatment",
                            "PrimaryOutcomeDescription": "Here is the number of non-serious adverse events probably related to treatment assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).",
                            "PrimaryOutcomeTimeFrame": "During treatment and up to 30 days after the first follow- up evaluation (at the second follow-up evaluation)"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells",
                            "SecondaryOutcomeDescription": "Participants blood samples were assessed by fluorescence-activated cell sorting (FACS), enzyme-linked immune absorbent (ELISA)-spot and human soluble cluster of differentiation 137 (CD137) (4-1BB) upregulation assays. Differences of 2-3 fold in these assays over the baseline measures are indicative of true biologic difference.",
                            "SecondaryOutcomeTimeFrame": "Approximately 2 weeks after last vaccine"
                        }
                    ]
                },
                "OtherOutcomeList": {
                    "OtherOutcome": [
                        {
                            "OtherOutcomeMeasure": "Number of Participants With Non-Serious Adverse Events Regardless of Attribution",
                            "OtherOutcomeDescription": "Here is the count of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence.",
                            "OtherOutcomeTimeFrame": "Date treatment consent signed to date off study, approximately 11 months and 4 days."
                        },
                        {
                            "OtherOutcomeMeasure": "Number of Dose Limiting Toxicities (DLT)",
                            "OtherOutcomeDescription": "A DLT is all Grade 3 or greater toxicities related to the messenger ribonucleic acid vaccine with exception of Grade 3 fever, Grade 3 pruritic/itching, Grade 3 fatigue, Grade 3 metabolic laboratory abnormalities without significant clinical sequela that resolves to Grade 2 or less within 7 days, Grade 3 autoimmune toxicity that resolves to Grade 2 or less in 7 days and events that are clearly related to the patient's disease.",
                            "OtherOutcomeTimeFrame": "Up to 21 days after the first vaccination"
                        },
                        {
                            "OtherOutcomeMeasure": "Maximum Tolerated Dose (MTD",
                            "OtherOutcomeDescription": "A MTD is the highest dose at which \u22641 of 6 patient's experienced a dose limiting toxicity (i.e., All Grade 3 or greater toxicities related to the messenger ribonucleic acid vaccine with exception of Grade 3 fever, Grade 3 pruritic/itching, Grade 3 fatigue, Grade 3 metabolic laboratory abnormalities without significant clinical sequela that resolves to Grade 2 or less within 7 days, Grade 3 autoimmune toxicity that resolves to Grade 2 or less in 7 days and events that are clearly related to the patient's disease.) or the highest dose level studied if DLT's are not observed at any of the dose levels.",
                            "OtherOutcomeTimeFrame": "Up to 21 days after the first vaccination"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "INCLUSION CRITERIA:\nMeasurable (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria), metastatic melanoma, gastrointestinal, or genitourinary cancer with at least one lesion that is resectable. Only patients with metastatic gastrointestinal cancer will be eligible for enrollment on the Phase I portion of the study. Patients with metastatic melanoma, gastrointestinal, or genitourinary cancer will be eligible for enrollment on the Phase II portion of the study.\nConfirmation of diagnosis of metastatic cancer by the National Cancer Institute (NCI) Laboratory of Pathology.\nPatients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n\nPrior therapy with at least one first-line standard of care treatment or second-line treatment of proven effectiveness. Patients must have progressive disease after prior treatment. Prior first-or second-line treatments would include the following:\n\nPatients with metastatic melanoma: Receipt of a checkpoint inhibitor as first-line therapy\nPatients with metastatic melanoma with an activating mutation of KIT: Receipt of Imatinib\nPatients with a BRAF V600 activating mutation: Receipt of appropriate targeted therapy\nPatients with metastatic gastrointestinal cancer: Receipt of up to two forms of approved first- and/or second-line chemotherapy regimens\nPatients with metastatic genitourinary cancers: Receipt of a first- or second-line therapy appropriate for their histologic subtype\nAge greater than or equal to 18 years and less than or equal to 70 years.\nClinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.\n\nSerology\n\nSeronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\nSeronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by reverse transcription polymerase chain reaction (RT-PCR) and be hepatitis C virus (HCV) ribonucleic acid (RNA) negative.\n\nHematology\n\nAbsolute neutrophil count (ANC) > 1000/mm(3) without the support of growth factors.\nWhite blood cell (WBC) greater than or equal to 3000/mm(3)\nPlatelet count greater than or equal to 100.000/mm(3)\nHemoglobin > 8.0 g/dl. Subjects may be transfused to reach this cut-off.\n\nChemistry\n\nSerum Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) less than or equal to 5.0 times upper limit of normal (ULN)\nSerum creatinine <1.5 times ULN or measured creatinine clearance (calculated using Cockcroft-Gault formula) > 40 ml/min\nTotal bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dl.\nMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the immunization regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).\nAbility of subject to understand and the willingness to sign a written informed consent document.\nSubjects must be co-enrolled on protocol 03-C-0277.\n\nEXCLUSION CRITERIA:\n\nPregnant or breastfeeding women who do not consent to stop breast-feeding while on study treatment and for 30 days after the use of the investigational vaccine where pregnancy is confirmed by a positive, rising human chorionic gonadotropin (hCG) laboratory test.\n\nWomen of child-bearing potential, defined as all women capable of becoming pregnant, unless they agree to use an appropriate method of contraception during dosing and for 120 days after the last dose (i.e., final vaccine). Effective contraception methods include a combination of any two of the following (unless method is abstinence or sterilization, in which only one method is required):\n\nUse of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%). In case of use of oral contraception, women should have been stable on the same pill for a minimum of 6 months before taking study treatment.\nPlacement of an intrauterine device or intrauterine system.\nBarrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.\nTotal abstinence\nFemale sterilization at least eight weeks before taking study treatment.\nMale sterilization (at least six months prior to screening).\nSexually active males must use a condom during intercourse during dosing and for 120 days after the last dose (i.e., final vaccine), and should not father a child in this period.\nAny systemic steroid therapy or other form of immunosuppressive therapy within 7 days of the first dose of the vaccine. A physiologic dose of systemic corticosteroids may be approved. Inhaled or topical steroids, and less than or equal to 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\nActive systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses of the cardiovascular, respiratory, or immune system.\nAny form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\nConcurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).\nAny vaccinations four weeks prior to the first vaccination cycle or live vaccines at any time during the study.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "70 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Steven A Rosenberg, M.D.",
                            "OverallOfficialAffiliation": "National Cancer Institute (NCI)",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "National Institutes of Health Clinical Center",
                            "LocationCity": "Bethesda",
                            "LocationState": "Maryland",
                            "LocationZip": "20892",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "19935803",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol. 2009 Dec;9(12):833-44. doi: 10.1038/nri2669."
                        },
                        {
                            "ReferencePMID": "23243587",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology. 2012 Nov 1;1(8):1239-1247. doi: 10.4161/onci.21285."
                        },
                        {
                            "ReferencePMID": "20085707",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Abramson J, Giraud M, Benoist C, Mathis D. Aire's partners in the molecular control of immunological tolerance. Cell. 2010 Jan 8;140(1):123-35. doi: 10.1016/j.cell.2009.12.030."
                        },
                        {
                            "ReferencePMID": "33016924",
                            "ReferenceType": "derived",
                            "ReferenceCitation": "Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020 Nov 2;130(11):5976-5988. doi: 10.1172/JCI134915."
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "Two step registration process. Step One: Patient signed consent to create vaccine. Step Two: Once vaccine is available, patient screened for eligibility criteria. If eligibility criteria were met, registration and enrollment was completed and the patient was treated. One patient died between Step one and Step two and was not treated.",
                "FlowRecruitmentDetails": "No participants were enrolled on Dose Level 1 - 0.04mg vaccine, nor Cohort 2a/2b, Arm 2, Phase II Maximum Tolerated Dose Arm/Group. Participants vaccination started on Dose Level 2 - 0.13 mg.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                            "FlowGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                        },
                        {
                            "FlowGroupId": "FG001",
                            "FlowGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                            "FlowGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                        },
                        {
                            "FlowGroupId": "FG002",
                            "FlowGroupTitle": "Cohort 2a/2b, Arm 2, Phase II Maximum Tolerated Dose",
                            "FlowGroupDescription": "(2a) Melanoma and (2b) Gastrointestinal or Genitourinary cancer patients receive the maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Phase I",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "3"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "2"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "Received Intervention",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "2"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "2"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "2"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "2"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "1"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Signed consent. Died before treatment.",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG002",
                                                    "FlowReasonNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "FlowPeriodTitle": "Phase II",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselinePopulationDescription": "No baseline data was collected for the participant that signed consent for vaccine but died before treatment.",
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                            "BaselineGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                        },
                        {
                            "BaselineGroupId": "BG001",
                            "BaselineGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                            "BaselineGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                        },
                        {
                            "BaselineGroupId": "BG002",
                            "BaselineGroupTitle": "Total",
                            "BaselineGroupDescription": "Total of all reporting groups"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "2"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG001",
                                        "BaselineDenomCountValue": "2"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG002",
                                        "BaselineDenomCountValue": "4"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "42",
                                                                "BaselineMeasurementSpread": "4"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "51",
                                                                "BaselineMeasurementSpread": "6"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "46.5",
                                                                "BaselineMeasurementSpread": "6.4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Number of Participants Who Had a Clinical Response (Complete Response + Partial Response) to Treatment (Objective Tumor Regression)",
                            "OutcomeMeasureDescription": "Clinical response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "up to 12 months",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "2"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Complete Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Partial Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Stable Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Progressive Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Not Evaluable",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Number of Non-Serious Adverse Events Probably Related to Treatment",
                            "OutcomeMeasureDescription": "Here is the number of non-serious adverse events probably related to treatment assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "adverse events",
                            "OutcomeMeasureTimeFrame": "During treatment and up to 30 days after the first follow- up evaluation (at the second follow-up evaluation)",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg Starting Dose",
                                        "OutcomeGroupDescription": "Gastrointestinal Cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "2"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Nausea",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Vomiting",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells",
                            "OutcomeMeasureDescription": "Participants blood samples were assessed by fluorescence-activated cell sorting (FACS), enzyme-linked immune absorbent (ELISA)-spot and human soluble cluster of differentiation 137 (CD137) (4-1BB) upregulation assays. Differences of 2-3 fold in these assays over the baseline measures are indicative of true biologic difference.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "Approximately 2 weeks after last vaccine",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "2"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Other Pre-specified",
                            "OutcomeMeasureTitle": "Number of Participants With Non-Serious Adverse Events Regardless of Attribution",
                            "OutcomeMeasureDescription": "Here is the count of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "Date treatment consent signed to date off study, approximately 11 months and 4 days.",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular injections (IM) on Days 0, 14, 28, and 42."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "2"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Other Pre-specified",
                            "OutcomeMeasureTitle": "Number of Dose Limiting Toxicities (DLT)",
                            "OutcomeMeasureDescription": "A DLT is all Grade 3 or greater toxicities related to the messenger ribonucleic acid vaccine with exception of Grade 3 fever, Grade 3 pruritic/itching, Grade 3 fatigue, Grade 3 metabolic laboratory abnormalities without significant clinical sequela that resolves to Grade 2 or less within 7 days, Grade 3 autoimmune toxicity that resolves to Grade 2 or less in 7 days and events that are clearly related to the patient's disease.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "toxicities",
                            "OutcomeMeasureTimeFrame": "Up to 21 days after the first vaccination",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "2"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Other Pre-specified",
                            "OutcomeMeasureTitle": "Maximum Tolerated Dose (MTD",
                            "OutcomeMeasureDescription": "A MTD is the highest dose at which \u22641 of 6 patient's experienced a dose limiting toxicity (i.e., All Grade 3 or greater toxicities related to the messenger ribonucleic acid vaccine with exception of Grade 3 fever, Grade 3 pruritic/itching, Grade 3 fatigue, Grade 3 metabolic laboratory abnormalities without significant clinical sequela that resolves to Grade 2 or less within 7 days, Grade 3 autoimmune toxicity that resolves to Grade 2 or less in 7 days and events that are clearly related to the patient's disease.) or the highest dose level studied if DLT's are not observed at any of the dose levels.",
                            "OutcomeMeasurePopulationDescription": "MTD was not reached.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Up to 21 days after the first vaccination",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                                        "OutcomeGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsTimeFrame": "Date treatment consent signed to date off study, approximately 11 months and 4 days.",
                "EventsDescription": "Two step registration process. Step One: Patient signed consent to create vaccine. Step Two: Once vaccine is available, patient screened for eligibility criteria. If eligibility criteria were met, registration and enrollment was completed and the patient was treated. One patient died between Step one and Step two and was not treated.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 2 - 0.13mg",
                            "EventGroupDescription": "Gastrointestinal cancer patients receive 0.13mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42.",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "2",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "2",
                            "EventGroupOtherNumAffected": "2",
                            "EventGroupOtherNumAtRisk": "2"
                        },
                        {
                            "EventGroupId": "EG001",
                            "EventGroupTitle": "Cohort 1, Arm 1, Phase I - Dose Level 3 - 0.39mg",
                            "EventGroupDescription": "Gastrointestinal cancer patients receive 0.39mg of messenger ribonucleic acid (mRNA) vaccine as intramuscular (IM) injections on Days 0, 14, 28, and 42.",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "2",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "2",
                            "EventGroupOtherNumAffected": "2",
                            "EventGroupOtherNumAtRisk": "2"
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventNotes": "Possibly related to research.",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventNotes": "Possibly related to research.",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fever",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Flu like symptoms",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Injection site reaction",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Shingles",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritus",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, excoriation to the head of penis",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chills",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (5.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "0",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "2"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "No",
                    "AgreementRestrictiveAgreement": "No"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Steven Rosenberg",
                    "PointOfContactOrganization": "National Cancer Institute",
                    "PointOfContactEMail": "steven-rosenberg@nih.gov",
                    "PointOfContactPhone": "240-858.3080"
                }
            }
        },
        "DocumentSection": {
            "LargeDocumentModule": {
                "LargeDocList": {
                    "LargeDoc": [
                        {
                            "LargeDocTypeAbbrev": "Prot_SAP",
                            "LargeDocHasProtocol": "Yes",
                            "LargeDocHasSAP": "Yes",
                            "LargeDocHasICF": "No",
                            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                            "LargeDocDate": "January 23, 2019",
                            "LargeDocUploadDate": "03/24/2020 13:27",
                            "LargeDocFilename": "Prot_SAP_000.pdf"
                        },
                        {
                            "LargeDocTypeAbbrev": "ICF",
                            "LargeDocHasProtocol": "No",
                            "LargeDocHasSAP": "No",
                            "LargeDocHasICF": "Yes",
                            "LargeDocLabel": "Informed Consent Form",
                            "LargeDocDate": "January 28, 2019",
                            "LargeDocUploadDate": "03/24/2020 13:28",
                            "LargeDocFilename": "ICF_001.pdf"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000005770",
                            "ConditionMeshTerm": "Gastrointestinal Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000008113",
                            "ConditionMeshTerm": "Liver Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000006528",
                            "ConditionMeshTerm": "Carcinoma, Hepatocellular"
                        },
                        {
                            "ConditionMeshId": "D000014565",
                            "ConditionMeshTerm": "Urogenital Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009370",
                            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005767",
                            "ConditionAncestorTerm": "Gastrointestinal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000008107",
                            "ConditionAncestorTerm": "Liver Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000000230",
                            "ConditionAncestorTerm": "Adenocarcinoma"
                        },
                        {
                            "ConditionAncestorId": "D000002277",
                            "ConditionAncestorTerm": "Carcinoma"
                        },
                        {
                            "ConditionAncestorId": "D000009375",
                            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                        },
                        {
                            "ConditionAncestorId": "D000052776",
                            "ConditionAncestorTerm": "Female Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005261",
                            "ConditionAncestorTerm": "Female Urogenital Diseases and Pregnancy Complications"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M11218",
                            "ConditionBrowseLeafName": "Melanoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M9303",
                            "ConditionBrowseLeafName": "Carcinoma, Hepatocellular",
                            "ConditionBrowseLeafAsFound": "Hepatocellular Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M10803",
                            "ConditionBrowseLeafName": "Liver Neoplasms",
                            "ConditionBrowseLeafAsFound": "Hepatocellular Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafAsFound": "Gastrointestinal Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafAsFound": "Genitourinary Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M12005",
                            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10797",
                            "ConditionBrowseLeafName": "Liver Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M3275",
                            "ConditionBrowseLeafName": "Adenocarcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12010",
                            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26783",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M13817",
                            "ConditionBrowseLeafName": "Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8089",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases and Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2854",
                            "InterventionBrowseLeafName": "Immunomodulating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}